|
Stockholders' Equity (Details Textual) (USD $)
|
1 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Dec. 23, 2003
|
Dec. 31, 2013
|
Dec. 31, 2012
|
Dec. 31, 2013
Common Stock [Member]
|
Dec. 31, 2013
Accredited Investors [Member]
|
Dec. 31, 2013
Underwritten Offering [Member]
|
Dec. 31, 2013
Performance Shares [Member]
|
Jun. 28, 2013
Restricted Stock [Member]
|
Dec. 31, 2013
Restricted Stock [Member]
|
Dec. 31, 2010
Restricted Stock [Member]
|
Dec. 31, 2013
Restricted Stock Award [Member]
|
Dec. 31, 2013
2011 Equity Incentive Plan
|
|
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 1,783,292 | |||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant | 304,673 | |||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights | Ten percent of the issued restricted common stock vested on December 31, 2011. The remaining ninety percent of the restricted shares were modified on January 31, 2013 to vest on the earlier of the first dosing in the pivotal clinical study for its lead drug candidate, or 50% on January 31, 2014 and 50% on January 31, 2015. | |||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 5.75 | $ 0 | ||||||||||
| Treasury Stock, Shares, Acquired | 8,626 | |||||||||||
| Treasury Stock Acquired, Average Cost Per Share | $ 6.16 | |||||||||||
| Share-based Compensation, Total | $ 979,151 | $ 127,488 | $ 16,000 | |||||||||
| Class Of Warrant Or Right Issued | 20,467 | |||||||||||
| Class Of Warrant Or Right Exercise Price Of Warrants Issued | $ 12.21 | |||||||||||
| Class Of Warrant Or Right Amended Expiration Date | Dec. 31, 2015 | |||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 12,000 | 112,720 | ||||||||||
| Stock Issued During Period, Shares, New Issues | 1,715,800 | 6,336,664 | 1,715,800 | 15,000 | ||||||||
| Proceeds from Issuance of Common Stock | 12,809,126 | 0 | 35,700,000 | 12,500,000 | ||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 907,336 | |||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Exercise Price, Beginning Balance | $ 2.81 | |||||||||||
| Allocated Share-based Compensation Expense | 979,151 | 127,488 | 422,000 | |||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award | the Company modified the vesting terms for its unvested performance based stock options and unvested restricted common stock of fifteen employees and non-employee directorsto vest on the earlier of the first closing in the pivotal clinical study for its lead drug candidate, or 50% on January 31, 2014 and 50% on January 31, 2015. | the Company modified 907,336 existing time-vested and performance stock options by lowering the exercise price to $2.81. Additionally, the Company modified the vesting terms for its unvested performance stock options and unvested restricted stock to vest on the earlier of the first dosing in the pivotal clinical study for its lead drug candidate, or 50% on January 31, 2014 and 50% on January 31, 2015 | ||||||||||
| Payments of Stock Issuance Costs | 2,300,000 | 1,600,000 | ||||||||||
| Stock Issued During Period, Value, Issued in Settlement for Termination of Certain Rights in Stock Purchase Agreement | 913,446 | 15 | ||||||||||
| Stock Issued During Period, Shares, Issued in Settlement for Termination of Certain Rights in Stock Purchase Agreement | 152,241 | |||||||||||
| Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | $ 12,000 | $ 0 | ||||||||||